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There is a crack in everything 
That's how the light gets in.




A complete understanding of the pathogenesis of diabetic neuropathy continues to be elusive and as a result, progress in developing effective therapies has been disappointing. 
In particular, there is only limited understanding of why some patients suffer severe chronic pain, whilst others have painless symptoms. Assessment of the peripheral nerves frequently shows no differences between painful and painless diabetic peripheral neuropathy (DPN). There is growing evidence that the nerve damage in DPN is more generalized, involving the entire nervous system including the central nervous system (CNS). The advent of new radiological techniques, such as magnetic resonance spectroscopy (MRS) provides us with non-invasive modalities to study pathophysiological processes in greater detail.
In addition, although a clear link between DPN and cardiac autonomic neuropathy (CAN) is recognised, the relationship of autonomic neuropathy with sub-types of DPN is less clear. The development of novel and sensitive measures of CAN, such as spectral analysis of heart rate variability (HRV), may allow the detection of subclinical abnormalities not detected by conventional autonomic function tests (AFT).
The principal aim of this thesis was to better understand the nature of the relationship between painful and painless DPN with other parts of the nervous system, namely the CNS and the autonomic nervous system. In the first study the central processing of sensation in people with diabetes was assessed to determine whether central mechanisms have an important role in the perception of pain. In the second study, short-term HRV analysis was used to help define the nature of the relationship between CAN and painful and painless DPN more clearly. A secondary aim was to develop and validate a model incorporating HRV parameters as a sensitive measure of autonomic dysfunction.
In the first study, 110 subjects with type 1 diabetes (20 no DPN, 30 subclinical DPN, 30 painful DPN and 30 painless DPN) and 20 healthy volunteers (HV) underwent detailed clinical and neurophysiological assessments (Dyck's NIS(LL)+7 staging criteria). They all underwent proton magnetic resonance spectroscopy of the left thalamic nucleus and somatosensory cortex to measure established markers of neuronal function using long echo time (LET) and neuronal integrity using short echo time (SET) spectroscopic sequences.
The results demonstrated significant differences between painful and painless DPN. In the thalamus, at LET, subjects with painless DPN had significantly lower N-acetylaspartate (NAA) compared to other groups (ANOVA p<0.001). No differences were seen at SET. In contrast, in the somatosensory cortex, no inter-group differences were seen at LET, but at SET, the painless DPN group had lower NAA, compared to HV and subjects with diabetes but no DPN, whilst subjects with painful DPN had intermediate levels (ANOVA p<0.001). Various other differences were also seen between painful and painless DPN in other cerebral neurochemicals (particularly myo-inositol and glutamate), despite no differences between the groups in detailed peripheral nerve assessments. These results suggest that astrocyte dysfunction within a hyperglutaminergic state within the thalamus may be a key factor in the development of painful DPN.
In a second study, a subset of these patients (20 HV, 20 no DPN, 20 painful DPN and 20 painless DPN) underwent short-term HRV analysis, to assess sympathovagal modulation of the heart rate. Various frequency domain and time domain parameters were assessed. The results showed that despite no differences in conventional AFT, subjects with painful DPN had greater autonomic abnormalities when assessed using HRV analysis, suggesting that it is a more sensitive tool to detect autonomic dysfunction. The greater autonomic dysfunction seen in painful DPN may reflect more predominant small fibre involvement and adds to the growing evidence of its role in the pathophysiology of painful DPN.
In the third study, we demonstrated that this method of HRV analysis can be used to develop a sensitive tool to detect early autonomic dysfunction. Using discriminant function analysis, a model was developed which incorporated 8 HRV parameters as well as basic demographic data. It demonstrated a high degree of sensitivity and specificity. 
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1.1  Diabetes Mellitus
Diabetes Mellitus is a complex metabolic disorder that is manifested by chronic hyperglycaemia. It results in disturbances of carbohydrate, fat and protein metabolism that are a consequence of defects in insulin secretion, insulin action, or both. 
1.1.1  Diagnosis and Classification
There are two main forms of diabetes: type 1 and type 2, which have different causes and patient populations. Whilst, ultimately, all types of diabetes are due to the failure of beta cells to produce enough insulin to prevent hyperglycaemia, the pathophysiology is quite different. Type 1 diabetes (T1DM) is thought to be predominantly due to autoimmune destruction of beta cells resulting in an absolute insulin deficiency. Type 2 diabetes (T2DM) is characterised by reduced insulin sensitivity (frequently termed “insulin resistance”) in target tissues. Although in the early stages beta cells are able to produce enough insulin (hyperinsulinaemia) to overcome this resistance and prevent hyperglycaemia, ultimately they cannot meet this demand. This is probably due to a combination of worsening insulin resistance (e.g. due to weight gain) and beta cell failure. In contrast to T1DM therefore, there is a relative insulin deficiency.  
There is a large list of other specific types of diabetes such as diabetes caused by gene defects; diabetes secondary to pancreatic disease; diabetes secondary to other endocrine disorders or drugs. Gestational diabetes refers to glucose intolerance or diabetes diagnosed during pregnancy.
The World Health Organisation (WHO) criteria for the diagnosis of diabetes are based on either the fasting plasma glucose or 2 hour plasma glucose after a 75g oral glucose tolerance test (OGTT). Table 1 shows the current diagnostic criteria for diagnosing diabetes as well as impaired fasting glucose (IFG) and impaired glucose tolerance (IGT).

Table 1 WHO Criteria for diagnosis of diabetes based on a 75g OGTT


1.1.2  Long Term Complications of Diabetes




Figure 1 Common complications of diabetes

There is now a substantial body of evidence that implicates hyperglycaemia in the development of all of these long-term complications. In addition, the benefit of improved glycaemic control in preventing the development of microvascular, and to a degree macrovascular, complications has been demonstrated in both T1DM, in the Diabetes Control and Complications Trial (DCCT, 1993) and in T2DM, in the UK Prospective Diabetes Study (UKPDS, 1998).
Just how chronic hyperglycaemia leads to complications is not yet fully understood, but it is likely that the underlying pathology is that of endothelial dysfunction. A number of different and complex mechanisms have been implicated in the pathogenesis of endothelial dysfunction, but the exact importance of each of these individual mechanisms in the development of different complications is not yet clear. It is likely, however, that they all have a role to play in the development of endothelial dysfunction and may explain why many trials looking at interventions targeting individual mechanisms have been generally disappointing. Table 2 lists a summary of the various proposed mechanisms.

Proposed mechanisms for the development of complications in diabetes
Polyol pathway hyperactivityAdvanced glycation end product formationOxidative stressIncreased protein kinase C activityDirect glucotoxicityFamilial and genetic aspects




1.1.2.1  Microvascular Complications
Chronic hyperglycaemia results in a variety of metabolic and haemodynamic insults that eventually lead to the development of microangiopathy. Although initially functionally reversible, there is eventual structural change, with increased small vessel permeability, thickening of the basement membrane and luminal narrowing (Zatz and Brenner, 1986). Figure 2 shows an electron photomicrograph of a capillary taken from a nerve biopsy in a patient with diabetic neuropathy. It shows marked thickening of the basement membrane with proliferation of the endothelial cells leading to virtual occlusion of the lumen. 


Figure 2 Photomicrograph from a capillary from a nerve biopsy in diabetic neuropathy 
(Image courtesy of S. Tesfaye)

This ultimately leads to complete obstruction, resulting in tissue hypoxia and eventual damage and failure. Depending on the site of the microvascular damage, reparative mechanisms can be induced. These mechanisms, however, are often abnormal and can be responsible for further tissue damage and dysfunction. For example, in diabetic retinopathy, tissue ischaemia leads to the development of new vessels (neovascularisation) in the retina (Figure 3). These new vessels, however, are structurally abnormal and more fragile, making them prone to leakage and haemorrhage.(Goh and Tooke, 2002) 


Figure 3 Retinal photograph of proliferative diabetic retinopathy 
with neovascularisation and haemorrhages

Although patients with T1DM and T2DM are both prone to developing microvascular complications, there are distinct differences in their manifestation. As T2DM has often been present for up to 10 years before being diagnosed, many patients will present with evidence of microvascular complications at the time of diagnosis. In T1DM, complications usually develop between 10-20 years after diagnosis. Visual loss in T1DM is usually due to proliferative retinopathy, whereas in T2DM, maculopathy is the predominant cause. In T1DM, nephropathy is usually due to the classical microvascular damage leading to albuminuria. In contrast, in T2DM, there are often multiple factors involved, including hypertensive nephropathy and renovascular disease.(Fioretto et al., 1998)




1.2  Diabetic Neuropathy
Diabetic neuropathy is one of the most frequent complications of diabetes.  It is a source of great distress, disability and premature death.  It is the main initiating factor for foot ulceration and the commonest cause of non-traumatic lower limb amputation in the western world. The projected increase in the prevalence of diabetes will have important associated health implications both in terms of morbidity and mortality as well as being a major burden on scarce medical resources.
Diabetic neuropathy is not a single entity, but comprises several neuropathic syndromes, of which the commonest is chronic distal symmetrical peripheral neuropathy.

1.2.1  Classification 
Diabetic neuropathy is defined as “the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after the exclusion of other causes” (Boulton et al., 1998). Careful clinical examination is essential as many subjects are asymptomatic or have other non-diabetic neuropathies (e.g. chronic inflammatory demyelinating polyneuropathy). 
Peripheral nerve damage in diabetes mellitus can be broadly separated into generalised symmetrical polyneuropathies and focal neuropathies. Clinical classification of the various syndromes of diabetic neuropathy has proved very difficult.  The variation and overlap in aetiology, clinical features, natural history and prognosis have meant that most classifications are necessarily oversimplified and none has proved capable of accounting for all of these factors.  In 2005, the American Diabetes Association (ADA), in a consensus statement, proposed a classification shown in Table 3 (Boulton et al., 2005). It is based on the premise that diabetic neuropathy is not a unitary condition, but is the result of a number of disturbances in the peripheral nervous system as a consequence of hyperglycaemia (Boulton et al., 2004b). 
Focal and Multifocal Neuropathies
CranialTruncalFocal LimbProximal motor (amyotrophy)
Generalised Symmetric Polyneuropathies 
Acute sensoryChronic sensorimotorAutonomic
Table 3 Classification of Diabetic Neuropathy

1.2.1.1  Focal and Multifocal Neuropathies
Focal Limb Neuropathies
Focal limb neuropathies are frequently due to entrapment and reflect the increased susceptibility of the nerves affected to compression in diabetes. The most common entrapment neuropathy is carpal tunnel syndrome (due to entrapment of the median nerve), causing pain and paraesthesia in the hands. It can be demonstrated electrophysiologically in up to 20-30% of people with diabetes, although is only symptomatic in around 6% (Wilbourn, 1999). It is three times more common in diabetes compared to the non-diabetic population (Karpitskaya et al., 2002). Other nerves affected include the ulnar nerve, radial nerve, common peroneal nerve, and lateral femoral cutaneous nerve (Boulton et al., 2004b).
Cranial Neuropathies
Cranial neuropathies in people with diabetes are very rare. Ocular neuropathies affecting the III, IV, and VI nerves are the most common. The classical presentation in most textbooks is of an acute III nerve palsy causing diplopia and ptosis, but with pupillary sparing (due to preservation of sympathetic nerve fibres that run on the outside of the nerve). Although pupillary sparing is often quoted as being pathognomic of diabetic neuropathy, pupillary dysfunction is a common finding in diabetes due to the co-presence of autonomic neuropathy (Moster, 1999). Although other cranial neuropathies are even rarer, the presence of diabetes is a common finding in most case series of idiopathic VII nerve neuropathy (Bell’s palsy) (Abraham-Inpijn et al., 1982). 
Diabetic Amyotrophy
Diabetic amyotrophy (or proximal motor neuropathy) is most commonly seen in people with type 2 diabetes aged between 50-60 years. It frequently occurs in the context of initiation of treatment or rapidly improving control and is associated with significant weight loss. Severe deep pain in the thigh is often the initial symptom, but this is usually later superseded by marked proximal weakness as the main limiting factor. The patient usually complains of difficulty in getting out of a chair or climbing stairs and in severe cases can lead to them being confined to a wheelchair. On examination there is marked wasting of the quadriceps muscles. Sensory involvement is relatively unusual and usually reflects a co-existing distal sensory neuropathy. (Sander and Chokroverty, 1996) 
The pathophysiology is not clear but is thought to be due to ischaemic damage to immune-mediated microvasculitis (Dyck and Windebank, 2002).
In the majority of cases, the pain usually starts to subside after 3 months and usually settles completely after 1 year (Coppack and Watkins, 1991). Management is largely supportive, predominantly to control the pain.
Truncal Radiculopathies
Diabetic truncal radiculopathies are characterised by a painful (often burning or stabbing in nature) neuropathy, in a dermatomal distribution in the lower thorax or abdomen (Stewart, 1989). These are usually unilateral and are often accompanied by hyperaesthesia and marked weight loss. Rarely motor weakness can cause bulging of the anterior abdominal wall (Boulton et al., 1984). In those presenting with abdominal pain and weight loss, it is often poorly diagnosed, resulting in patients undergoing unnecessary gastro-intestinal investigations for neoplasia. It bears many similarities to diabetic amyotrophy and also usually resolves within 12 months (Kikta et al., 1982).

1.2.1.2  Generalised Symmetrical Polyneuropathies
Acute Sensory Neuropathy
Acute sensory neuropathy is an uncommon syndrome associated with periods of poorly controlled diabetes, as well as sudden improvements in glycaemic control (so called “insulin neuritis”). It is characterised by acute or sub-acute onset of severe painful symptoms, in glove and stocking distribution, usually with nocturnal exacerbation. Despite the intensity of symptoms, there is often little objective abnormality found on examination or neurophysiological assessments.  Clinical tests of sensory function are often normal and nerve conduction velocities are usually only mildly reduced. The most consistent abnormality is loss of small fibre function on quantitative sensory testing, often in association with allodynia (Boulton et al., 2004b). 
In the context of poor glycaemic control there is usually accompanying precipitous weight loss, initially described by Ellenberg as “neuropathic cachexia” (Ellenberg, 1974).
Paradoxically, acute painful neuropathy has also been described following rapid improvements in glycaemic control (Ellenberg, 1958, Archer et al., 1983).This is usually in the context of insulin use (as well as in insulinomas) and has therefore been termed “insulin neuritis”.  There have been virtually no reports of a similar syndrome following rapid improvements in control after initiation of oral hypoglycaemic therapy, or pancreatic or islet cell transplantation (Leow and Wyckoff, 2005). The pathophysiology is unclear. Metabolic effects such as hypoglycaemia and hyperinsulinaemia have been shown to induce nerve injury in animal models (Sima et al., 1989). Using fluorescein angiography and in vivo epineurial vessel photography, Tesfaye et al have also demonstrated epineurial arterio-venous shunting and new vessel formation (similar to diabetic retinopathy). They hypothesised that sudden change in glycaemic control leads to a “steal” effect and endoneurial ischaemia, suggesting the importance of vascular factors in the pathogenesis of neuropathic pain (Tesfaye et al., 1996a).
In both cases, establishment of stable glycaemic control usually results in gradual improvement of symptoms, usually over 8-12 months (Archer et al., 1983).
Autonomic Neuropathy
Diabetic autonomic neuropathy (DAN) is a serious complication of diabetes and carries up to a five-fold increased risk of mortality (O'Brien et al., 1991). This high mortality rate is related in large part to silent myocardial ischaemia, cardiac arrhythmias, and cardio-respiratory instability. Despite its relationship to an increased risk of cardiovascular mortality and its association with significant morbidity, the importance of DAN is not fully appreciated and it frequently goes undiagnosed. A major reason for this is that whilst severe symptomatic DAN is relatively uncommon, many people have sub-clinical or asymptomatic DAN.





Features of Autonomic Neuropathy
Cardiovascular	Genitourinary
Resting tachycardiaExercise intoleranceOrthostatic hypotensionSilent myocardial ischaemia	Neurogenic bladderErectile dysfunctionRetrograde ejaculationFemale sexual dysfunction
GI	Sudomotor
Oesophageal dysmotilityGastroparesisConstipationDiarrhoeaFaecal incontinence	AnhidrosisHeat intoleranceGustatory sweatingDry skin
Metabolic		Pupillary
Hypoglycaemia unawareness	Pupillomotor function impairmentArgyll Robertson pupil
Table 4 Features of Autonomic Neuropathy

Methods of testing the autonomic nervous system range from simple blood pressure estimation with postural change to monitoring R-R variation (using electrocardiographic monitoring software) with deep breathing, Valsalva manoeuvre and postural changes.  There is however a wide variability with repeat testing, which can be minimised by standardizing the methodology and using a central testing facility (Low and Pfeifer, 1993). 
Chronic Sensorimotor Neuropathy
This is the most common and widely recognised form of diabetic neuropathy.  This diabetic peripheral neuropathy (DPN) is usually insidious in onset and can present in a variety of different forms. It also has a major impact on the ability to function normally (both mental and physical functioning e.g. ability to maintain work), mood and quality of life. As DPN was the focus of this thesis, the remainder of this review will focus on its key features.
1.2.2  Clinical Features
Up to half of patients will complain of a variety of different symptoms. These range from burning pain, lancinating or electric shock-like sensations, paraesthesia, hyperaesthesia or contact allodynia, and deep aching pain. Other patients may describe negative symptoms such as numbness or their feet feeling “dead”. It is important to be aware that up to half of patients will be entirely asymptomatic and the diagnosis only apparent on clinical examination. Often, the first time the neuropathy is diagnosed is when the patient presents with a painless foot ulcer. Sensory loss dominates the early stages, starting at the toes and gradually progressing into the feet and legs. 
When the disease is well established in the lower limbs in more severe cases, there is upper limb involvement, with a similar progression proximally starting in the fingers. As the disease advances further, motor manifestations, such as wasting of the small muscles of the hands and limb weakness, become apparent.  Motor nerve involvement is usually sub-clinical, although it is easily detectable on neurophysiological testing (Andersen et al., 1997).  Non-invasive imaging techniques have revealed atrophy of the musculature of the foot and this may be visible clinically in severe cases (Andersen, 1999).  However, early and predominant motor involvement or asymmetry should raise the possibility of alternative diagnoses, such as CIDP (Boulton et al., 1998).
Painful DPN can cause severe distress. It is characteristically more severe at night resulting in a high prevalence of sleep disorders. The unremitting nature of the pain can be highly distressing resulting mood disorders including depression and anxiety.(Gore et al., 2005) This has a high social and economic burden. 
On clinical examination, there is usually a symmetrical ascending sensory loss in a stocking distribution. The hands can also be affected in more severe cases. Reflexes (especially ankle) are often reduced or absent. Wasting of the small muscles of the feet is frequently seen, leading to deformities such as clawing of the toes and subluxation of the metatarsal heads. This leads to abnormal pressure loading and the development of callus, a precursor to ulcer development. Local autonomic neuropathy also leads to a shiny, dry appearance to the feet (decreased sweating) and prominent veins (arterio-venous shunting). Fissures can form in areas of dry, calloused skin and be sources of introducing infection. There is also often accompanying peripheral vascular disease, which increases the vulnerability of the foot to developing complications. Loss of proprioception can also lead to unsteadiness and a positive Romberg’s sign (Boulton et al., 1998).
1.2.3  Epidemiology
Measuring the prevalence of neuropathy has been confounded by a lack of a consensus over diagnostic criteria, the wide variety of measurement techniques used and the subject selection for study.  As a result the prevalence of diabetic neuropathy has been shown in clinical and population based studies to vary from 8% to 66% depending on the criteria used to diagnose neuropathy, as well as the nature of the population being assessed (Dyck et al., 1993a). It can be present in up to 10% of newly diagnosed patients with type 2 diabetes (UKPDS, 1998, Partanen et al., 1995) and is more common with increasing age and duration of diabetes.
One of the most definitive studies was the population-based Rochester Diabetic Neuropathy Study, which assessed neuropathy using a composite score based on clinical symptoms and signs, quantitative sensory testing, autonomic function tests and nerve conduction studies. The prevalence of some form of neuropathy was 66% in type 1 and 59% in type 2 diabetes (Dyck et al., 1993a). 
More recently, the Eurodiab study described a prevalence of neuropathy of 28% in 3250 subjects across Europe with type 1 diabetes (Tesfaye et al., 1996b). In those without neuropathy at baseline, the incidence was 24% over 7 years. In this study, neuropathy was diagnosed if there were more than two abnormalities amongst symptoms, lower limb reflexes, vibration perception threshold, and autonomic function tests (change in heart rate or blood pressure on standing). The incidence of neuropathy was related to the glycosylated haemoglobin (HbA1c) and duration of diabetes. After adjustment for these, they found that higher cholesterol, higher triglycerides, higher body mass index (BMI), higher urinary albumin excretion ratio (UAER), hypertension, and smoking were significantly associated with the cumulative incidence of neuropathy. After adjustment for other risk factors and other complications, the duration of diabetes, HbA1c, BMI, and smoking were all independently associated with the incidence of diabetic neuropathy. Cardiovascular disease at baseline was associated with double the risk of incident neuropathy (Tesfaye et al., 2005).
There have been relatively few epidemiological studies that have specifically examined the prevalence of painful DPN. In a recent study of a large cohort of diabetic patients receiving community-based health care in northwest England (n = 15,692), painful DPN assessed using neuropathy symptom and disability scores was found in 21% (Abbott et al., 2011). In one population-based study from Liverpool, UK, the prevalence of painful DPN assessed by a structured questionnaire and examination was estimated at 16% (Daousi et al., 2004).  Notably, it was found that 12.5% of these patients had never reported their symptoms to their doctor and 39% had never received treatment for their pain, indicating that there may be considerable under-diagnosis and under-treatment of painful neuropathic symptoms compared to other aspects of diabetes management such statin therapy and management of hypertension.  
1.2.4  Pathogenesis






Changes in sodium channel distribution and expression Changes in calcium channel distribution and expressionAltered neuro-peptide expressionSympathetic sprouting				  Peripheral sensitization				   Altered peripheral blood flowAxonal atrophy, degeneration or regenerationDamage to small fibresIncreased glycemic flux
Central Mechanisms
Central sensitizationAβ fibre sprouting into Aβ fibre sprouting intoReduced inhibition of descending pathways
Table 5 Mechanisms of Neuropathic Pain 
(Adapted from Tesfaye and Kempler 2005)

1.2.5  Management
The mainstay of treatment for neuropathy currently is prevention, mainly by delaying its onset.  Once DPN is established, it is generally thought to be irreversible and progressive. Recently, there has been some evidence of improvements in small fibre morphology in the cornea following pancreas-kidney transplantation, using a technique called corneal confocal microscopy (Tavakoli et al., 2013). No improvement however has been demonstrated in large or small fibre numbers or function in peripheral nerves following transplantation. Although it has been suggested that changes seen on corneal confocal microscopy are surrogate markers of peripheral nerve function, the significance of these findings remain controversial.  Aims of treatment should therefore be directed at reducing symptoms and slowing the progression of neuropathy.
There is good evidence that strict glycaemic control reduces the incidence of DPN.  In type 1 diabetes, the DCCT showed that intensive insulin treatment reduced the incidence of DPN by as much as 50% in both the primary and secondary prevention cohorts (DCCT, 1995).  In type 2 diabetes, stricter control of blood glucose was associated with less deterioration in vibration perception threshold (UKPDS, 1998).  This benefit was however, far less than that observed in the DCCT.  In the STENO 2 study, type 2 diabetes patients were divided into two treatment cohorts (Gaede et al., 2008).  One cohort received conventional treatment and the other intensive treatment to tackle the multiple risk factors for DPN.  This included antihypertensive drugs e.g. angiotensin converting enzyme inhibitors and calcium channel antagonist, hypoglycaemic agents, aspirin, lipid lowering agents and anti-oxidants.  There was a 0.32 reduction in the odds ratio for developing autonomic neuropathy, but this study did not show a reduction in the risk of developing DPN.
Numerous treatments aimed at countering the proposed pathogenic mechanisms of DPN have been through rigourous clinical trials.  Despite early promising results, many of these compounds have failed to make sufficient impact and hence are not widely licensed or available.  There are however, a few treatments that have been granted licenses for use in certain countries e.g. alpha-lipoic acid in Germany and the aldose reductase inhibitor, epalerestat, in Japan. 
Alpha-lipoic acid is an endogenous, sulphur-containing, free radical scavenger found in mitochondria. Free radicals can reduce nitric-oxide-mediated vasodilation and damage to the vascular endothelium (Cameron and Cotter, 1997b).  Alpha-lipoic acid also recycles other antioxidants, such as vitamins E and C. Clinical trials have shown that treatment with alpha-lipoic acid improves distal nerve conduction. A systemic review of 15 randomised clinical trials concluded that alpha-lipoic acid could be considered as a treatment option for diabetic patients with mild to moderate neuropathy, but many of the trials had poor methodology (Han et al., 2012). Intravenous administration is probably superior to oral administration.
Aldose reductase inhibitors reduce glucose flux through the polyol pathway and lower accumulation of toxic sorbitol. In a Cochrane review,19 trials, testing four different aldose reductase inhibitors between 4 – 208 weeks duration (median 24 weeks) were subjected to a meta-analysis (Airey et al., 2000).  The review concluded that although aldose reductase inhibitors treatment diminished the reduction in motor nerve conduction velocity, the clinical relevance of such a change was uncertain.  
The assessment and treatment of painful DPN is ideally done in the context of a multidisciplinary team (MDT). When treatment is started a realistic objective would be to achieve around 50% reduction in pain intensity. Secondary objectives should include restoration or improvement in functional measures, quality of life, sleep and mood. Management should include consideration of non-pharmacological therapies, such as psychological interventions. (Tesfaye et al., 2011)
Although strong evidence implicates poor glycemic control as a pathogenic mechanism in the aetiology of DPN, there is no proof from randomised, controlled trials that this is the case for neuropathic pain in diabetes.  However, as increased blood glucose flux has been reported to contribute to pain in DPN (Oyibo et al., 2002), there is a general consensus that good blood glucose control should, with the current level of knowledge, be the first step in the management of any form of diabetic neuropathy.
Pharmacological treatment of painful DPN is not entirely satisfactory as currently available drugs are often ineffective and complicated by adverse events. Tricyclic compounds have been used as first line agents for many years but many patients fail to respond to them and anti-cholinergic side effects including dry mouth, constipation, sweating, blurred vision, sedation, orthostatic hypotension (with the risk of falls particularly in elderly patients) are frequent (Tesfaye et al., 2011). Higher doses have been associated with an increased risk of sudden cardiac death thus caution should be taken in any patient with a history of cardiovascular disease (Ray et al., 2004).
The selective serotonin noradrenalin reuptake inhibitor (SNRI), duloxetine, has been used for the management of painful DPN. SNRIs relieve pain by increasing synaptic availability of 5-hydroxytryptamine and noradrenalin in the descending pathways that inhibit pain impulses (Tesfaye et al., 2011).  The efficacy of Duloxetine in painful DPN has been investigated in three identical trials and pooled data from these shows that the 60 mg/day and 120 mg/day doses are effective in relieving painful symptoms, starting within a week and lasting the full treatment period of 12 weeks (Kajdasz et al., 2007).  The main side effects include nausea, somnolence, dizziness, constipation, dry mouth and reduced appetite although these tend to be mild to moderate and are transient.
The anticonvulsant gabapentin, that binds to the α-2-δ subunit of the calcium channel thereby reducing neurotransmitter release in the hyperexcited neurone, is also effective (Backonja et al., 1998). More recently, there have been several clinical trials involving pregabalin in painful DPN, and these showed clear efficacy in management of painful DPN (Freeman et al., 2008). Although other anticonvulsants, particularly carbamazepine, have been extensively used to treat painful DPN, robust evidence for their efficacy is very lacking.
Other effective drugs for painful DPN include: tramadol, a weak opioid and weak inhibitor of noradrenaline and serotonine reuptake (Sindrup et al., 1999, Harati et al., 1998) and the strong opioid, oxycodone (Gimbel et al., 2003); and topical treatments including topical capsaicin, which depletes substance P (Biesbroeck et al., 1995). There is limited evidence that lignocaine patches may also be effective (Barbano et al., 2004). Refractory cases may be treated intravenous lignocaine. (Tesfaye et al., 2011)
One of the difficulties in deciding the optimal pharmacological therapy for painful DPN is the lack of large, robust randomised clinical trials comparing different therapies, as well as the efficacy of combination therapies. The need for this level of evidence has been highlighted by recent consensus guidelines (O'Connor and Dworkin, 2009).
A recent large multicentre, double-blind, parallel-group study (COMBO-DN) compared pregabalin vs. duloxetine vs. a combination of the two drugs (Tesfaye et al., 2013). After an initial 8 week run in period, when subjects (n=804) were randomised to pregabalin 300mg/day or duloxetine 60mg/day, non-responders (n=339) received either high dose pregabalin (600mg/day), high dose duloxetine (120mg) or combination therapy at the lower doses (pregabalin 300mg and duloxetine 60mg daily). There was no difference in the primary outcome of change in pain scores between the three groups, although duloxetine (60mg/day) did seem to be superior to pregabalin (300mg/day) with regard to improvement in pain scores after the initial 8 week period.
There is a limited amount of evidence that non-pharmacological treatments, based on small single-centre studies, may be effective in some cases. These treatments include acupuncture (Abuaisha et al., 1998), electromagnetic neural stimulation (Bosi et al., 2005) and percutaneous electrical stimulation (Hamza et al., 2000). There is evidence that psychological therapies may be of some benefit in chronic pain (Eccleston et al., 2009), but studies specific to painful DPN are lacking. A small recent study did however suggest that cognitive behaviour therapy may be beneficial (Otis et al., 2013)


2  Assessment of Neuropathy
2.1  Clinical Assessment of Neuropathy
The methods available for the detection and quantification of diabetic neuropathy are numerous and varied.  The clinical setting usually governs the technique used to assess diabetic neuropathy. In a busy annual review diabetic clinic, for example, where the main concern is identifying individuals at risk for foot ulceration then careful clinical examination, inspection of footwear and devices such as a monofilament or a pinprick will suffice (Boulton et al., 1998).  For epidemiological studies, techniques such as vibration perception threshold (VPT) are usually a minimum requirement.  On the other hand, when greater diagnostic accuracy is required (e.g. clinical intervention trials) expensive computer-assisted and laboratory-based techniques are employed.  
Testing of all sensory modalities will reveal abnormalities in a “glove and stocking” distribution.  Individual modalities tested will provide clues to the type of nerve fibres affected.  For example impairment of vibration perception (128Hz tuning fork) and joint position sense reflect predominant large fibre neuropathy.  On the other hand, defective warm and cold thermal discrimination is in keeping with predominant small nerve fibre involvement.  The use of ankle reflexes and vibration testing has been advocated in guidelines for screening for diabetic neuropathy (ADA, 2001). There is, however, greater evidence in the literature for the use of the Semmes-Weinstein 5.07 (10g) monofilament (Perkins et al., 2001).  The monofilament is a cheap, simple, rapid, reproducible screening tool for peripheral diabetic neuropathy, which can be used in a busy diabetic clinic.  An abnormal monofilament test is associated with a three year relative risk as high as 15 for the development of ulceration or amputation (Rith-Najarian et al., 1992).  The monofilament is applied to a non-callused site on the dorsum of the first toe just proximal to the nail bed. It is repeated four times on both feet in an arrhythmic manner.  Five or greater insensate stimuli are associated with a very high probability of peripheral diabetic neuropathy (Perkins et al., 2002).
If there is sensory loss of the upper limb in a glove distribution, then the level of impairment in the legs has to have reached mid thigh.  If not, another explanation for the upper limb sensory loss ought to be sought.  Motor weakness is usually mild and confined to the feet.  As the disease progresses severe distal weakness limits a subject’s ability to stand/walk on the heels or toes. Loss of proprioception leads to an unsteady gait and a positive Romberg test.
2.2  Quantifying diabetic neuropathy in clinical trials
For the purposes of clinical trials more detailed assessment tools have been devised to diagnose and monitor neuropathy progression.  The reason for this is because, unlike retinopathy (direct visualisation) and nephropathy (microalbuminuria), there isn’t an accepted simple, single biomarker, which can monitor the natural history of diabetic neuropathy. A number of scoring systems have therefore been developed to aid the collection and analysis of multiple different variables and provide a quantitative value, which can be followed longitudinally.  These range from the simple systems based on evaluation of symptoms and neurological examination, such as the Michigan Neuropathy Score (Feldman et al., 1994) or the Toronto Clinical Scoring System (Bril and Perkins, 2002), to more detailed systems, which also include more formal assessments of nerve function.  The current gold standard assessment tool, validated to diagnose and monitor diabetic neuropathy over time is the Neuropathic Impairment Scale of the lower limbs plus seven neurophysiological tests (NIS[LL] + 7 tests) (Dyck et al., 1992).  This is a composite score calculated by assigning scores to percentile abnormalities in nerve conduction studies, vibration detection threshold and autonomic function tests (variation in heart rate during deep breathing) into scores and combining them with together a score obtained from detailed lower limb neurological examination.  Based on the calculated composite score, the severity of neuropathy can be staged in individual subjects (Table 6 and 7 show details of the Dyck staging system).  According to Dyck et al. a minimum composite score of > 4.5 is required to diagnose DPN. This score is greater than the 97.5th percentile for the composite score and was judged to be better than other published minimal criteria, as well as individual measures of DPN, in identifying subjects with DPN (i.e. at least stage N1).  It has been validated as a very sensitive tool to assess the state and dynamics of peripheral neuropathy over time (Dyck et al., 1997, Dyck and Thomas, 1999). 





No polyneuropathy.  Less than N1a
N1
N1a: Asymptomatic polyneuropathy as recognised by nerve conduction​ abnormality in at least two nerves or heartbeat deep breathing abnormality, caused by DPN.N1b: N1a criteria plus neurologic examination abnormality or abnormality on quantitative sensory testing of vibration detection threshold or cooling detection threshold.
N2
N2a: Symptomatic mild DPN.  Sensory autonomic or motor symptoms caused by DPN.  Neuropathic impairment is the same or more than N1a.  Patients has less than 50% weakness of ankle dorsiflexor muscles (able to walk on heels)N2b: Symptomatic severe DPN.  Neuropathic impairment is the same or more than N1a.  Patient has 50% or greater weakness of ankle dorsiflexor muscles (unable to walk on heels).
N3
Disabling DPN










Calculating the Neuropathy Impairment Score of the Lower Limbs plus seven tests of nerve function (NIS LL + 7). 
Sum individual scores of the NIS for the lower limbs NIS (LL) (items 17—24, 28 and 29, and 34—37 of the NIS).
In the NIS (LL) substitute transformed points for percentile abnormality* of vibration detection threshold for each great toe (obtained with CASE IV) for the clinical vibration sensation point score of great toes.
Add transformed points for percentile abnormality* of heartbeat variation with deep breathing (one time only).
Sum transformed points for percentile abnormality* of the five attributes of nerve conduction of lower limbs (peroneal nerve (CMAP, MNCV and MNDL), tibial nerve (MNDL) and sural nerve (SNAP) and divide by the number of attributes with obtainable values#, multiply by 5 (the number of attributes), and add this to the global score.
Table 7 Calculating the NIS(LL) + 7 Score
CMAP, compound muscle action potential; MNCV, motor nerve conduction velocity; MNDL, motor nerve distal latency; SNAP, sensory nerve action potential.
 *< 95th = 0, > 95th—99th = 1, > 99th—99.9th = 2, and > 99.9th = 3 (or > 5th = 0…< 0.1th = 3, whichever end of the distribution is abnormal);





Table 8 Neuropathy Impairment Scale (NIS)
NIS(LL) refers to items 17-24, 28-29, 34-37. Reflexes and sensation are scored as 0-normal, 1-reduced, 2-absent. Muscle power is scored at 0 (normal), 1 (25% weak), 2 (50% weak), 3 (75% weak), or 4 (paralysis). Adjustments are made for age (in over 60’s, absent reflexes score 0).
2.3  Assessing neuropathic pain severity




3  Magnetic Resonance Spectroscopy in diabetic neuropathy
3.1  Introduction
As discussed earlier, diabetic neuropathy is a common and unpleasant complication of diabetes mellitus and is the main initiating factor for foot ulceration (Tesfaye et al., 1996b).  With the increasing prevalence of diabetes there are important associated health implications in terms of morbidity, as well as considerable consumption of scarce medical resources (Johnson and Williams, 1997).  The pathogenesis of diabetic neuropathy remains unclear despite extensive research that has focused on metabolic (Cameron and Cotter, 1997b) and vascular factors (Tesfaye et al., 1994, Ward and Tesfaye, 1997, Malik et al., 1993, Yasuda and Dyck, 1987) and the complex interactions between them (Yagihashi, 1995, Cameron and Cotter, 1997a). As a result, progress in the development of an effective therapy has been disappointing and a complete understanding of the pathogenesis of this condition continues to be elusive.
3.1.1  Central Nervous System Involvement in Diabetic Neuropathy
Most clinical research into diabetic neuropathy has concentrated on the functional and structural aspects of the peripheral nerve (Giannini and Dyck, 1999, Tesfaye et al., 1996a, Newrick et al., 1986). There is increasing evidence that the nerve damage in diabetic neuropathy may be more generalised and potentially important areas such as the spinal cord and the brain may have been overlooked.  Post mortem studies in diabetic subjects have revealed microvascular disease within the spinal cord and brain, similar to that seen in the peripheral nerve (Olsson et al., 1968, Reske-Nielsen and Lundbaek, 1968, Slager, 1978).  However, many of these studies did not specifically examine patients with peripheral neuropathy and so it is impossible to say whether these changes were due to neuropathy or diabetes.  More recent electrophysiological studies, using somatosensory evoked potentials, have shown slowing or attenuation of central conduction in diabetic neuropathy (Ziegler et al., 1993).
Using non-invasive MRI Selvarajah et al. demonstrated early spinal cord shrinkage in diabetic neuropathy (Selvarajah et al., 2006). A pattern of changes occurring at progressively higher centres in the nervous system is now becoming clear.  MRS and functional magnetic resonance provides us with non-invasive modalities to study these pathophysiological processes in greater detail.  Various deep nuclei within the brain involved in somatosensory perception and pain modulation have shown changes in neurochemical constitution in MRS studies of other models of neuropathy and chronic pain (Grachev et al., 2000, Pattany et al., 2002).  MRS studies of the brain in diabetes are limited. Spectroscopic changes in the brain were demonstrated in DM in one study (Perros et al., 1997), but no correlation with neuropathy was found and specific deep brain nuclei have not been studied. In a small study of just 7 subjects with DPN and “positive sensory symptoms”, higher Glx to γ-aminobutyric acid ratios were found in the posterior insula and thalamus in DPN patients compared to healthy volunteers (HV) (Petrou et al., 2012). The authors suggested that this may be indicative of alteration of the balance between excitation and inhibition within the pain processing network in the brain. A further small study by Sorenson et al. examined spectroscopic changes in the thalamus and sensory cortex in 14 subjects with painless DPN and 12 with painful DPN (Sorensen et al., 2008). They demonstrated lower levels of NAA in the thalamus in painful DPN compared to painless DPN. 
Thus, a better understanding of the changes that occur within these key areas may allow the identification of early, potentially reversible, changes amenable to therapeutic intervention.  Therapeutic interventions could then be tailored to match the heterogeneity of the mechanisms involved in the pathogenesis of neuropathy.
3.1.2  Magnetic Resonance Spectroscopy
The advent of magnetic resonance spectroscopy (MRS) has allowed the non-invasive assay of the products of gene expression and cerebral metabolites (Currie et al., 2013). It is essentially a measure of brain physical chemistry. Conventional MR imaging (MRI) uses the magnetic polarisation of hydrogen atoms in water molecules to build up a detailed spatial picture of body tissues, MRS takes this a step further by studying the hydrogen atoms in other molecules. This is possible as the hydrogen atoms in different molecules resonate at different frequencies. The spectra produced consist of numerous peaks corresponding to different cerebral metabolites (Currie et al., 2013). 
Theoretical Background
Historically, MRS was used in the 1950’s/60’s for ‘bench top’ chemical analyses prior to the development of MRI in the 1970’s. The basic principles of MRS are the same as those for MRI. Put simply, the interaction between atomic nuclei and applied radio waves (in the presence of an external, homogeneous, static magnetic field) gives rise to the production of an electromagnetic signal in the non-ionising, radiofrequency part of the electromagnetic spectrum. This interaction is a resonance phenomenon. The signal that is produced decays over time as a result of the relaxation of nuclei from their excited to relaxed (equilibrium) states. The frequency of resonance depends on the size of the magnetic field in which the protons (hydrogen nuclei) are placed. Protons in different molecules resonate at different frequencies, as the magnetic field to which they are exposed is affected by the local electron cloud configuration. Thus, if placed within a large homogeneous static magnet, hydrogen nuclei within water molecules (H20) experience a slightly different magnetic field than hydrogen nuclei attached to fat molecules (-CH2 and -CH3) and this causes the protons attached to each of these molecular groups (H20, -CH2, -CH3) to resonate at slightly different frequencies. A Fourier transformation is then used to separate the signal into its different component frequencies. (Currie et al., 2013)
In conventional MRI, the total proton signal is used. As by far the dominant signal is from water and lipid, if the entirety of the signal is used in MRS, the other metabolite peaks would be invisible. The water signal is therefore suppressed, often by the use of Gaussian chemical-shift selective (CHESS) pulses (Zhu and Barker, 2011). 
In MRI, an image is formed by encoding the signal by the rapid application and removal of magnetic field gradients (this leads to the production of acoustic noise within the scanner). In MRS, similar ‘spatial encoding’ of the signal can be achieved in different ways. Early MRS used the spatial response of a detection coil to locate the signal. More precise localisation can be achieved with single voxel localisation or low-resolution, chemical shift imaging (CSI) techniques (Currie et al., 2013). The latter is technically more demanding and susceptible to various spectral artefacts; all of the work in this thesis was performed using single-voxel spectroscopy (SVS) methods, which detect signal from the intersection of 3 orthogonal slices, forming the ‘voxel’. 
The detection of unwanted fat is avoided by placing the voxel within the region of interest (ROI) in the brain and thereby avoiding fat within the bone marrow and scalp (Zhu and Barker, 2011). The formation of the signal (excitation) and its localisation were carried out using 2 different acquisition techniques. Stimulated Echo Acquisition Mode (STEAM) uses three 90º radiofrequency pulses (90º, -90º, -90º), each of which defines the selection of a slice by the simultaneous application of a magnetic field gradient. It is most suitable for short echo time (SET) sequences, but at the expense of lower signal to noise for a given echo time. The Point Resolved Spectroscopy (PRESS) technique involves a double spin echo (90º, -180º, -180º) which, again, are applied at the same time as slice-defining gradients. It is more useful for long echo time (LET) sequences. The echo time affects the information obtained by MRS. At SET, metabolites with both long and short relaxation times are seen and these include NAA, choline (Cho), creatine (Cr), myo-Inositol (mI) and glutamate/ glutamine (Glx). The signal obtained at SET is, to a first approximation, proportional to the concentration (or proton-density) of the detected resonance.  At LET, only metabolites with long relaxation times are seen; namely NAA, Cho and Cr. The signal obtained at LET is T2-weighted and can thus be influenced by the chemical environment within the ROI. (Zhu and Barker, 2011)











The five main metabolite peaks that were assessed in this study are described below:

N-acetyl aspartate (NAA) 
NAA is one of the most prevalent amino acids in the brain. Immunohistochemical studies have shown that it is confined entirely to neuronal cell bodies and axons (Simmons et al., 1991). Most observations with MRS support the formulation of NAA as a neuronal marker. Its loss can occur in diseases in which neuronal loss is documented;  glioma, stroke, most dementias and hypoxic encephalopathy all show loss of NAA (Soares and Law, 2009, Zhu and Barker, 2011). 
Creatine (Cr)
The Cr peak originates from intracellular creatine and phosphocreatine. They are involved in creatine kinase reaction and it is therefore a marker of energy metabolism. It is relatively unchanged in most disease states and is often therefore used as a relative internal standard. In particular, at LET sequences this allows the concentration of other metabolites to be displayed as a ratio compared to Cr levels (Bradley, 2007) if various assumptions regarding the T2’s of the metabolites are made. Lower Cr peaks can be seen in cerebral lesions such as tumours and infections (reflecting the increased metabolism or the presence of necrosis). Spectroscopic levels can also be influenced by some systemic disorders (e.g. renal disease) (Soares and Law, 2009).
Choline (Cho)
This peak represents choline and choline containing compounds (such as phosphorylcholine and glycerophosphorylcholine) and are the breakdown products of cellular membranes.  Cho is therefore regarded as a marker of cell turnover. Increased Cho levels have been described in malignancy and inflammatory brain disorders. (Soares and Law, 2009, Law, 2009) 
Myo-Innositol (mI)
Myo-inositol is a cerebral osmolyte that acts as an osmoregulator in glial cells such as astrocytes. It is an accepted marker of astrocyte function and reductions in its level can represent astrocyte dysfunction or loss. Like choline, mI has been considered as a breakdown product of myelin because it is seen in apparently increased concentrations in multiple sclerosis plaques and human immunodeficiency virus (HIV) infections. (Grainger and Allison, 1997, Zhu and Barker, 2011)
Glutamate and glutamine (Glx)
Glutamate is the main excitatory transmitter in the brain, whilst glutamine is its precursor. Long term increase in glutaminergic neurotransmission results in central sensitisation. These two proteins are also involved in glucose metabolism and the Kreb’s cycle (Zhu and Barker, 2011).  They have been implicated in the induction of neuronal injury and apoptosis in neurodegenerative diseases; Glx concentrations are decreased in Alzheimer’s disease (Mattson, 2008).

3.2  Hypotheses
1.	There are structural and functional changes in the brain of patients with painless and painful diabetic neuropathy.
2.	The thalami and somatosensory cortex are likely to be the site of changes in the brain because of their central role in sensory perception.
3.	MRS and MRI will show evidence of structural and functional damage in the thalami and somatosensory cortex of volunteers with painful and painless neuropathy.
3.3  Aims
The initial pilot study using MRS showed abnormal thalamic function in patients with established neuropathy (Selvarajah et al., 2008).The aim of this study was to confirm these findings. We also looked at previously unexamined groups of patients - those with early neuropathy and painful neuropathy. 
We also looked at the spatial distribution of metabolites by investigating the MRS appearances within another cortical region, which is of critical importance in somatosensory perception, namely the somatosensory cortex.  In addition to providing evidence of neurochemical dysfunction within this region, it may provide insights into any differences between painful and painless diabetic neuropathy.
3.4  Subjects and Methods
3.4.1  Subjects
	20 healthy volunteers
	20 subjects with diabetes with no neuropathy (NIS(LL)+7 score < 1)
	30 subjects with diabetes with subclinical neuropathy (NIS(LL)+7 score between 1-4.5)
	30 subjects with diabetes with painless DPN (NIS(LL)+7 score > 4.5)
	30 subjects with diabetes with moderate/severe painful DPN
130 volunteers were recruited altogether as outlined above.  Neuropathy was staged in subjects with diabetes according to Dyck’s criteria (Dyck and Thomas, 1999), as described in the introduction; for the purposes of this study, a Dyck score of > 4.5 was used to define established DPN (both painful and painless). A score of < 1 was used to define no DPN, whilst a score of between 1 – 4.5 was used to define subclinical DPN. Patients with chronic painful neuropathy in which C-fibre symptoms predominate and persist for longer than six months were recruited into the painful group. A neuropathy pain questionnaire (McGill short form – see introduction for details) was used to verify painful DPN. A score of > 12/33 for sensory symptoms was necessary to qualify. In order to avoid changes in neurochemicals caused by the concomitant use of antidepressants and anticonvulsants, prior to scanning, volunteers (painful DPN group) were asked to discontinue these preparations for a period of two weeks. Subjects who were unable to discontinue these drugs for 2 weeks were not included in the study. An algorithm of alternative analgesia is shown in Table 9. 

Week one	Paracetamol, Aspirin
Week two (if further therapy is needed and indicated)	Nonsteroidal anti-inflammatory medications, Coproxamol
Table 9 Alternative analgesia protocol
If stronger analgesic preparations (class 2 or 3 controlled substances) were required, the patient was not included in the study.




	Type 1 Diabetes for > 5 years (Type 2 diabetes was excluded to avoid confounding variables such as the greater preponderance of vascular disease)
	Male subjects only (to avoid confounding variables such as brain size and structure due to sex differences) (Wilkinson et al., 1997)
	Only right handed volunteers will be included (to avoid confounding variables in brain structure and function due to differences in dominant side)
	Age 18-65 (to minimise age-related changes within the brain)
Exclusion criteria
	Previous cerebrovascular events or other neurological disorders.
	Use of antidepressants or antipsychotic medications.
	Psychiatric illnesses.
	Substance abuse.
	Contraindications for MR including claustrophobia.
	Previous history of consuming more than 20 units of alcohol a week. 
	Neuropathy due to other aetiology
	Estimated glomerular filtration rate < 45mmol/l
First visit
	Full history and examination (Neuropathy Impairment Score questionnaire) was performed on each patient.
	Subjects all completed a standard neuropathy pain questionnaire (McGill short form).
	Autonomic function, quantitative sensory testing (CASE IV system, WR Medical), and nerve conduction studies (CMAP, SNAP, distal latencies, amplitudes, F wave latencies of the radial, deep peroneal, tibial and sural nerves) were carried out in each case.
Second Visit
	Magnetic resonance imaging and spectroscopy studies
	Carried out within 28 days of first visit
3.4.2  MR Protocol 
MR imaging and spectroscopy was performed on a 1.5T system (Eclipse, Marconi Medical Systems, Cleveland, OH, USA) based in the Academic Unit of Radiology, Royal Hallamshire Hospital.  
All imaging was carried out according to standardised and well-established protocols.
All scans took approximately 60 minutes to perform.
In previous spectroscopy studies of other models of neuropathy, differences in concentrations of various neurochemicals (NAA, Cho, mI, and Glx) have been shown within various deep matter nuclei.  The most significant changes were noted within the thalamus and somatosensory cortex. (Grachev et al., 2000, Pattany et al., 2002)  We therefore chose to concentrate our efforts on these regions in this study.  The main rationale behind this was to minimise the time volunteers spend in the scanner; 60 minutes was considered to be the maximum tolerable period for a subject to lay still in the scanner.
Prior to spectroscopy, transaxial T2-weighted images (TE=90ms; TR=1050ms, ETL=16; 30 contiguous slices of thickness 5mm; acquisition matrix=256x256 over a 240mm field of view) were acquired. These images were used to guide the placement of a 3-dimensional voxel within the region of interest. Single-voxel spectra were obtained from 1cm3 areas of interest placed within the left thalamus to encompass the ventral posterior lateral sub-nucleus and 1cm x 1cm x 2cm areas of interest in the left precentral gyrus (S1 cortex), as shown in Figure 5. Care was taken to avoid/ minimise inclusion of ventricular cerebrospinal fluid (CSF) within the spectroscopic voxel. 

Figure 5 Axial section of the brain with voxel positioned to encompass a) the ventroposterior thalamic subnucleus and b) precentral gyrus

Two spectra were acquired from each subject:
1)	Long echo time (TE=135ms, TR=1600ms) using a PRESS technique (Figure 4.3).
2)	Short echo time (TE=20ms, TR=5000ms) a using a STEAM technique with a mixing time of 12ms (Figure 4.4).
The water signal was suppressed using CHESS, which pre-saturates the water signal using frequency selective pulses.
Assessment of measurement errors
A proportion of patients (n=12) were rescanned (within 3 months) to ascertain reproducibility of the various techniques in both normal and disease states. 
3.4.3  Data analysis 




3.5.1  Baseline Characteristics
Important baseline characteristics of the different groups are shown in Table 10. There was no statistical difference in terms of age between the painful and painless DPN groups, and HV. Not surprisingly, the no DPN and subclinical DPN groups were significantly younger (p<0.01). There was no significant difference in BMI between the groups. The subclinical DPN group had shorter duration of diabetes compared to the painless DPN group (p<0.01), but there was no other significant difference in duration of diabetes between the groups. The painful and painless DPN groups had poorer glycaemic control compared to the no DPN group (p<0.01). The painless DPN group had higher systolic blood pressure (SBP) compared to HV, no DPN and subclinical DPN groups (p<0.05). The painful DPN group had intermediate levels. There was no significant difference in the severity of neuropathy between the painful and painless DPN groups.
 	HV	No DPN	Subclinical DPN	Painful DPN	Painless DPN
Age (yrs)	53+15.2	46+9.4	43+7.1	55+13.1	55+10.4
BMI	26.6+4.1	27.0+4.2	25.2+3.9	28.7+4.4	28.3+4.4




Table 10 Baseline Characteristics of all 130 subjects who underwent MRS 




The intraclass correlation coefficient for thalamic NAA was 0.91 (p<0.001), which indicates strong agreement between the measurements. Cronbach’s alpha statistic was 0.953, which represents excellent internal consistency. Similar results were seen for the various other parameters that were measured.
3.5.3  Spectroscopic findings in the Thalamus
Table 11 shows all the results of the spectroscopic  findings at both SET and LET in the different groups. In the first analysis the NAA results were examined at both LET and SET. Figure 6 shows the results of MRS of the thalamus at a) LET and b) SET, respectively.  
At LET, subjects with painless DPN had significantly lower NAA : Cr ratio (1.55+0.22 [mean+SD]) compared to other groups [HV (1.80+0.23), no DPN (1.85+0.20), sub-clinical DPN (1.79+0.23), painful DPN (1.75+0.19),  p<0.01(post-hoc)]. There were no significant inter-group differences at SET. In addition, no significant differences were seen in NAA:Cho or Cho:Cr ratios within the thalamus at LET.












Table 11 Spectroscopic measurements in the thalamus 


Figure 6 Thalamus spectroscopy results for NAA
a) NAA:Cr Ratio (LET),   b) NAA Levels (SET) 
Error bars represent 95% CI   **p<0.001 (vs. all groups)

In the second analysis all the different neurochemical peaks at SET were examined. No significant differences were seen in the Cho or Cr normalised areas. Figure 7 shows the results for NAA, Glx and mI within the thalamus. As stated above there were no differences seen in thalamic NAA levels across the groups. Thalamic Glx in subjects with no DPN (0.83±0.29) was significantly higher compared with HV (0.57±0.22), painful DPN (0.64±0.27) and painless DPN (0.66±0.25), p<0.05. There was no significant difference in thalamic mI between HV, 0.39±0.15, no DPN, 0.4±0.16 and painless DPN, 0.45±0.19. Painful DPN, however, had lower thalamic mI, 0.32±0.19 compared to the other diabetic groups, p=0.02.

Figure 7 Thalamic neurochemical results at SET (NAA, mI, Glx)
Error bars represent 95% CI   
* p<0.05 vs. no DPN & painless DPN,  ** p<0.05 vs. HV, no DPN & painless DPN

3.5.4  Spectroscopic findings in the Somatosensory Cortex
Table 12 shows the results of the spectroscopic findings at both SET and LET in the different groups. 











Table 12 Spectroscopic measurements in the sensory cortex 

The first analysis examining the NAA results at a) LET and b) SET, respectively is shown in Figure 8. No statistically significant inter-group differences were seen at LET. At SET, the painless DPN group had lower NAA (0.62+0.08), compared to HV (0.73+0.15) and no DPN (0.68+0.13) groups, p=0.03. Subjects with painful DPN had intermediate levels (0.66+0.10) but no significant differences were apparent.


Figure 8 Sensory cortex spectroscopy results for NAA
a) NAA:Cr ratio (LET),   b) NAA Levels (SET)
Error bars represent 95% CI   *p<0.05 (vs. HV and no DPN)

In the second analysis all the different neurochemical peaks at SET were compared. No significant differences were seen in the Cho, Cr or mI peaks. Figure 9 shows the results for NAA, Glx and mI within the thalamus. In addition to the lower NAA levels in painless DPN (compared to HV and no DPN groups, see above), mean sensory cortex Glx in the HV group (0.37±0.06) was significantly lower compared to that of the no DPN (0.59±0.21), subclinical DPN (0.61±0.26) and painful DPN (0.61±0.22) groups, p<0.001. The painless DPN group (0.46±0.24) had a significantly lower mean Glx level than early DPN and painful DPN groups, p<0.05. 

 
Figure 9 Sensory cortex neurochemical results at SET (NAA, mI, Glx)
Error bars represent 95% CI  











In summary the results of this study show that in the thalamus, at LET, subjects with painless DPN had a significantly lower group mean NAA:Cr ratio compared to both the HV group and diabetes subjects without DPN. NAA has been shown to be largely confined to neuronal cell bodies and axons. The NAA:Cr ratio obtained at LET is thought to be more a measure of neuronal function rather than absolute integrity. The assumption that Cr remains relatively constant, implies that changes in the signal are due to NAA. The signal obtained at LET can reflect changes at T2, which can be influenced by the chemical surroundings within the ROI as well as the NAA concentration. Thus whilst changes may reflect neuronal loss, they may also be reflecting alterations in the chemical environment that could be affecting function. The lack of difference at SET suggests that there is no significant neuronal loss and changes seen at LET are due to a degree of thalamic neuronal dysfunction in painless DPN. Subjects with painful DPN, who clinically and neurophysiologically had the same severity of peripheral neuropathy, seemed to have relative preservation of thalamic neuronal function. These results imply change in neuronal physiology or function, rather than neuronal loss, within the thalamus (the gateway to the somatosensory cortex) in painless but not painful DPN. It is possible that relative preservation of thalamic neuronal function is necessary for the transmission of abnormal peripheral signals to higher centres and the perception of chronic pain in DPN.
In contrast, when the somatosensory cortex was examined, there was no difference at LET, but subjects with painless neuropathy had significantly lower levels of NAA at SET compared to both HV and diabetes subjects without DPN. As NAA levels at SET are thought to be a measure of neuronal integrity, it suggests a degree of neuronal loss in these subjects.  There are several possible hypotheses regarding the cause. Subjects with DPN are at greater risk of having other complications of diabetes, such as vascular disease (including small vessel arterial disease) and it may be that the changes seen are due to a general vascular effect of diabetes. The lack of changes seen in the thalamus at SET, however, make the hypothesis that this is a generalised vascular effect less likely. In addition, if this was an effect of underlying vascular disease, no difference would be expected between the painful and painless DPN groups as both were closely matched and likely to have similar levels of “disease burden”. An alternative theory is that these changes are due to an ascending “disuse atrophy”, caused by the lack of any sensory signals from the lower limbs being transmitted from the thalamus in painless DPN.  
These results are in contrast with the study by Sorenson et al. which showed lower NAA levels in the thalamus at SET in painful DPN, compared to painless DPN (Sorensen et al., 2008). This study was, however, potentially flawed in a number of aspects. In particular, the painful DPN group had a more severe degree of neuropathy compared to painless DPN (VPT 37.5 vs. 26.6 volts, p<0.01). 
The results for the other metabolites (mI, Cho, Cr and Glx) showed significantly higher levels of Glx in thalamus and sensory cortex in the no DPN group compared to the HV group perhaps suggesting a generalised effect of diabetes. Within the thalamus, there seems to be a decline in Glx with onset of neuropathy which may reflect the underlying neuronal dysfunction or loss. Subjects with painless DPN had lower levels of Glx within the somatosensory cortex compared to painful DPN. This in conjunction with the NAA results may reflect reduced neurotransmission due to neuronal loss/damage. There were lower levels of mI within the thalamus in subjects with painful DPN and this may reflect astrocyte dysfunction or loss. One possible hypothesis to explain these results is that diabetes is leading to a hyperglutaminergic state, which may ultimately be mediating neurotoxicity. Excessive activation of glutamate receptors, especially under conditions of oxidative or metabolic stress (diabetes being a prime example), have been implicated as contributing to the neuronal dysfunction and degeneration that occurs in a wide range of disorders such as strokes and Alzheimer’s dementia (Mattson, 2008). In painful DPN, astrocyte dysfunction within the thalamus, within this hyperglutaminergic state, may be resulting in a failure to recycle glutamate that has been released into synaptic spaces. As glutamate is an important excitatory neurotransmitter and involved in pain transmission, this in turn is leading to the persistence of pain and central sensitisation. Although over time, there may be a decline in absolute glutamate levels as neurones become increasingly dysfunctional, the astrocyte dysfunction leads to a persistence of abnormal levels of synaptic glutamate. In contrast, thalamic astrocyte function is preserved in painless neuropathy and as a result there is no increased neurotransmission to higher centres such as the sensory cortex. There is growing evidence that programmed cell death of neurones is activity-dependent; neurones which are stimulated by excitatory neurotransmitters, such as glutamate, survive, whilst those that lack activity may die. In part this may be related to the local release of neurotrophic factors such as brain-derived neurotrophic factor and nerve growth factor due to activation of glutamate receptors in the post-synaptic neurone (Mattson, 2008). This in turn may be leading to a degree of upstream “disuse atrophy”, as reflected by the lower NAA and Glx levels in the sensory cortex in painless DPN compared to painful DPN.
Because of constraints on the amount of time subjects were able to spend in the scanner, no spectroscopic measurements were carried out in a control area (i.e. in an area of the brain that is not involved in pain processing e.g. occipital cortex). This needs to be acknowledged as an important limitation when interpreting the results of this study. Another important limitation is the cross-sectional design of the study. Because of this, it is impossible to definitively assign causation to any of the differences seen. It may also have been helpful to have studied a group of subjects with a non-diabetic peripheral neuropathy to determine whether the changes seen are directly related to the peripheral neuropathy or are also influenced by the complex metabolic abnormalities that are specific to diabetes.
Nevertheless, this study has demonstrated, unlike most studies that have examined the peripheral nerve, that there are important differences in key areas and key neurochemicals of the brain in subjects with painful vs. painless DPN. Whether these apparent alterations are simply reflecting downstream changes (e.g. in the spinal cord), or are key drivers in the pathogenesis of different forms of neuropathy, or a combination of both, needs to be the subject of further studies. In particular, longitudinal studies need to be carried out to better understand the temporal relationships between these different abnormalities.


4  Autonomic Dysfunction in Painful and Painless Diabetic Neuropathy
4.1  Introduction
As already discussed, diabetic neuropathy is one of the most frequent complications of diabetes. The prevalence of some form of neuropathy has been reported to be as high as 66% in type 1 and 59% in type 2 diabetes (Dyck et al., 1993a).  It is the source of great distress, disability and premature death. It is also one of the least understood of all diabetic complications. One of the reasons for this is that diabetic neuropathy is not a single entity but describes a constellation of different syndromes affecting different parts of the nervous system, as described in the main introduction. Painless-DPN is the main initiating factor for foot ulceration and the commonest cause of non-traumatic lower limb amputation in the western world (Boulton et al., 2004a), whereas painful-DPN is associated with a variety of distressing symptoms that often have a major impact on quality of life. Autonomic neuropathy presents in multiple organ systems, of which cardiovascular involvement is the most serious. It is often asymptomatic until the early stages and is associated with significant mortality and morbidity. 
Although a clear relationship between DPN and cardiac autonomic neuropathy (CAN) has been recognised, the nature of the relationship of CAN with painless or painful neuropathy was less clear. Recently, there has been some evidence that at the level of the peripheral nerve, local autonomic dysfunction has an important role to play in the generation of pain (Quattrini et al., 2007). However, clinical studies looking to see if this translates into more generalised autonomic neuropathy have shown mixed, often opposite results (Young et al., 1986, Veves et al., 1994). Part of the reason for this may be because all of these studies used conventional autonomic function tests (AFT), that tend to detect autonomic dysfunction only at more advanced stages (Vinik and Ziegler, 2007). It is possible that more sensitive methods of detecting autonomic dysfunction might help determine whether subjects with painful DPN do have greater autonomic dysfunction, but there is currently a lack of evidence.
Over recent years a number of different techniques have been developed, which are more sensitive measures of autonomic function and are therefore able to detect subclinical abnormalities (Freeman, 2005). One such technique is spectral analysis of heart rate variability (HRV). Short-term HRV analysis is relatively quick and simple to carry out, as it is based on a 2-5 minute resting electrocardiographic (ECG) recording. It has been demonstrated to be able to detect autonomic dysfunction in subjects in whom conventional AFT are still normal (Weston et al., 1998).
4.2  Hypotheses
1.	Painful DPN is associated with greater autonomic dysfunction than painless-DPN.
2.	Any differences will principally be detected using HRV analysis, demonstrating its superiority to conventional AFTs in detecting subtle autonomic dysfunction. 
4.3  Aims
The aim of this study was to determine if there are differences in autonomic function between painful and painless DPN using spectral analysis of HRV. 
4.4  Subjects and Methods
4.4.1  Subjects
	20 subjects with T1DM and no DPN
	20 subjects with T1DM and painless DPN
	20 subjects with T1DM and painful-DPN
	20 healthy volunteers
80 subjects, as outlined above, were recruited. All subjects were aged between 18-70 years. Subjects with non-diabetic neuropathies, history of alcohol excess, significant left ventricular dysfunction (≥ NYHA Class III) or other cardiac problems that precluded HRV analysis, were excluded. All subjects gave written, informed consent before participation in the study, which had prior approval by the South Sheffield Regional Ethics Committee.
4.4.2  Neuropathy Assessment  
Subjects underwent detailed neurophysiological assessment in order to determine the presence and severity of neuropathy. The presence of painful symptoms was established using the McGill short form pain questionnaire (Melzack, 1975). Detailed neurological examination was graded by defined criteria using the standard NIS questionnaire (Grant et al., 1999). Sensory function was assessed by measuring vibration and cooling detection thresholds, acquired from the dorsal aspect of the right foot, using the Computer Assisted Sensory Evaluation IV (CASE IV, W.R. Electronics, Stillwater, MN, USA) system and employing standard techniques (Dyck et al., 1993b, Dyck et al., 1993c).  In addition, nerve conduction studies were carried out, at a stable skin temperature of 31˚C and a room temperature of 24˚C, using a Medelec electrophysiological system (Synergy Oxford Instruments, Oxford, UK).  The following nerve attributes were measured: i) sural sensory nerve action potentials and conduction velocities and ii) common peroneal and tibial motor nerve distal latency, compound muscle action potential and conduction velocity. Subjects also underwent conventional cardiac AFT performed with a computer assisted technique and evaluated using standard cardiovascular reflex tests based on O’Brien’s criteria: heart rate responses (R-R variation) at i) rest; ii) during deep breathing; iii) during Valsalva maneouvre; and iv) on standing (Pfeifer, 1999). 
Based on these clinical and neurophysiological assessments diabetic subjects were divided into three groups: i) No DPN consisting of asymptomatic subjects with normal clinical and neurophysiological assessments; ii) Painless DPN, comprising of subjects with both clinical and neurophysiological abnormalities (at least two abnormalities of neurophysiologic assessment), but no painful symptoms and iii) Painful DPN, with similar clinical and neurophysiological abnormalities and painful symptoms. A Neuropathy Composite Score (NCS) derived from the NIS(LL)+7 tests was calculated. This scoring system takes account of the neurological examination and neurophysiological assessments: the higher the NCS, the more severe the neuropathy. Details of the methodology have been set out previously in the introduction.
4.4.3  Spectral Analysis of Heart Rate Variability
HRV describes the timing variation between consecutive heartbeats (measured using the R-R interval on an ECG). A number of studies have validated it as a sensitive measure of autonomic function in diabetes (Freeman et al., 1991, Howorka et al., 1998).The regulation of HRV originates from both sympathetic and parasympathetic nervous systems and thus HRV can be used as a quantitative marker of autonomic function (Montano et al., 1994, Malik, 1996). Spectral analysis of HRV provides the basic information of how power of R-R variation distributes as a function of frequency (Figure 10). Three main components are observed in a spectrum calculated from R-R time series derived from short-term ECG recordings: (i) very low frequency (VLF), (ii) low frequency (LF), and (iii) high frequency (HF) components. Various time domain measures can also be calculated based on the intervals between successive normal complexes, so called normal to normal (NN) intervals. The commonest measures used are the standard deviation of the NN interval (SDNN) and the square root of the mean squared differences of successive NN intervals (RMSSD) (Niskanen et al., 2004, Malik, 1996). 

Figure 10 Spectral Analysis of HRV

HRV analysis was based on the recording of 5 minutes of ECG with the patient resting in a supine position after a period of adaptation. Subjects were advised to refrain from any caffeine or alcohol for 12 hours prior to the examination and any subjects with hypoglycaemia in the preceding 24 hours had their examination postponed. All examinations took place in the morning. The equipment required consisted of a standard ECG amplifier, a device to convert the analogue ECG signals into a digital format and a laptop computer to process and analyse the ECG using in-house developed software for HRV analysis (Petry et al., 2007). The software and digital signal processing algorithms followed established guidelines for HRV analysis (Malik, 1996). Frequency domain parameters of HRV analysed were power in the VLF range (<0.04 Hz), LF range (0.04-0.15 Hz), HF range (0.15-0.4 Hz), LF/HF ratio and total power (TP) of the spectrum (0.003-0.4 Hz). Time domain parameters of HRV analysed were SDNN and RMSSD. Figure 11 shows examples of the frequency domain analysis in a diabetes subject with no CAN and one with severe CAN.

Figure 11 Examples of spectral analysis of HRV analysis 
showing the R-R variability tracing and frequency domain plot in a diabetes subject with a) no CAN and b) severe CAN (note virtual abolition of peak within the LF and HF range in severe CAN).
4.4.4  Statistical Analysis
All analyses were performed using the statistical package SPSS 14.  All values are described as means ± standard deviation for continuous data and as percentages for categorical data.  HRV parameters were logarithmically transformed to adjust for skewness. One-way analysis of variance (ANOVA) was used to compare baseline characteristics between groups and least significant difference post-hoc testing to compare differences between groups. As age is recognised to be a significant influence on HRV, we also compared mean differences between groups using analysis of covariance (ANCOVA), using age as a covariate. Pearson’s correlation was used to study the linear relationship between HRV measurements and NCS. 

4.5  Results
4.5.1  Baseline Characteristics




	HV(n=20)	No DPN(n=20)	Painless DPN(n=20)	Painful DPN(n=20)	P-value (ANOVA)
Age (yrs)	46.6 (+14.7)	45.7 (+10)	52 (+9.7)	52.1 (+11.1)	ns
BMI 	27.9 (+9.2)	28 (+8.3)	28.9 (+4.5)	29.1 (+6.8)	ns
Duration of DM (yrs)	-	23.3 (+13)	27.1 (+11.4)	20.3 (+9.4)	ns
HbA1c (%)	-	7.7 (+1.3)	8.8 (+1.5)	8.6 (+1.5)	0.042
Total Chol (mmol/l)	4.7 (+0.6)	4.5 (+0.7)	4.5 (+0.9)	4.1 (+0.8)	ns
SBP (mmHg)	131 (+21)	135 (+14)	151 (+20)	141 (+19)	0.007
DBP (mmHg)	80 (+7)	77 (+9)	79 (+4)	77 (+8)	ns
Retinopathy (%)	-	35	90	75	0.001
Albuminuria (%)	-	10	44	47	0.02






Table 13 Baseline characteristics of 80 subjects who underwent AFT testing. 




4.5.2  Autonomic Function Test Results
Table 14 shows the results of conventional AFT and HRV analysis in the different groups. On conventional autonomic function testing, a significant difference was seen across the groups for all R-R variability results. Post-hoc subgroup analysis, however, showed no significant differences could be detected between painless and painful DPN. Not surprisingly, the majority of significant differences were between HV or no DPN compared with the two DPN groups. 





	HV(n=20)	No DPN(n=20)	Painless DPN(n=20)	Painful DPN(n=20)	P-value†(ANOVA)
Conventional Autonomic Function Tests
Resting HR	65.4 (+14.9)	68.6 (+13.6)	67.3 (+8.8)	70.3 (+8.6)	ns
R-R variation (rest)	1.21 (+0.09)	1.21 (+0.09)	1.14 (+0.08)	1.10 (+0.05)	<0.001
R-R variation (deep breathing)	1.47 (+0.27)	1.38 (+0.26)	1.24 (+0.16)	1.16 (+0.14)	<0.001
R-R variation (Valsalva)	1.49 (+0.24)	1.71 (+0.32)	1.37 (+0.16)	1.37 (+0.14)	<0.001
R-R variation (standing)	1.46 (+0.25)	1.38 (+0.22)	1.27 (+0.25)	1.21 (+0.19)	0.02
HRV Frequency Domain Analysis (log transformed values)
VLF	4.23 (+3.35)	3.55 (+3.6)	2.60 (+3.82)	1.62 (+3.5)	ns
LF	5.59 (+1.14)	5.23 (+1.32)	4.12 (+1.67)	3.31 (+1.49)	<0.001
HF	5.45 (+1.29)	4.41 (+1.57)	3.59 (+1.08)	2.67 (+1.56)*	<0.001
LF/HF	1.06 (+0.28)	1.26 (+0.39)	1.19 (+0.48)	1.57 (+0.97)	ns
TP	7.11 (+0.93)	6.55 (+1.14)	5.73 (+1.28)	4.79 (+1.51)*	<0.001
HRV Time Domain Analysis (log transformed values)
SDNN	3.52 (+0.43)	3.31 (+0.55)	2.91 (+0.65)	1.62 (+3.5)*	<0.001
RMSSD	3.39 (+0.54)	2.99 (+0.72)	2.58 (+0.69)	2.16 (+0.71)	<0.001
Table 14 Autonomic function test results using conventional methods and HRV analysis
All data are mean (±SD). 
† p-value (ANOVA) across all groups
*p<0.05 compared to painless DPN group on post-hoc testing.

Across all the groups a significant negative correlation was noted between NCS and LF (r = -0.64), HF (r = -0.55), TP (r = -0.68), SDNN (r = -0.64) and RMSSD (r = -0.54), p<0.001 (Figure 12).
There was a significant negative correlation between various spectral analysis parameters and traditional cardiovascular risk factors. The strongest correlations were with TP and the results between it and age (r=-0.29), HbA1c(r=-0.36), SBP(r=-0.23) and ACR(r=-0.35) are shown in Figure 13, all p<0.05. ACR was log-transformed to correct for skewness. No significant correlations were seen with duration of diabetes or total cholesterol.




Figure 12 Correlations between NCS and HRV variables






Figure 14 Correlation of Spectral Analysis with motor (common peroneal nerve & tibial) and sensory (sural nerve) peripheral nerve function.

4.6  Discussion
This study shows that subjects with painful DPN have significantly greater autonomic dysfunction compared to those with painless DPN in a carefully matched and well characterized population. These differences are only detected using spectral analysis of HRV. No significant differences were detected using conventional AFT. To our knowledge, HRV analysis has not previously been used to assess differences in autonomic function in subtypes of DPN. 
The detection of greater autonomic dysfunction in painful DPN compared to painless DPN has biological plausibility. Both pain sensation and autonomic function are mediated by small poorly myelinated and unmyelinated fibres (whereas the larger fibres tend to transmit sensations such as vibration and touch) and are therefore more likely to be vulnerable to the pathological processes that occur in diabetic neuropathy. Sorensen et al. have shown lower intraepidermal nerve fibre density in painful DPN without objective signs of neuropathy (Sorensen et al., 2006). In addition, it may be that at the level of the peripheral nerve, local autonomic dysfunction is leading to changes in epineural blood flow, which may have an important role to play in pain generation. It has previously been shown that patients with acute painful neuropathy, so called “insulin neuritis”, have abnormal epineural vessel anatomy and increased arterio-venous shunting (Tesfaye et al., 1996a). More recently, Eaton et al. demonstrated increases in sural nerve epineurial blood flow in painful DPN (Eaton et al., 2003). Quattrini et al. subsequently showed impairment of acetylcholine induced foot skin vasodilator response in painful DPN (Quattrini et al., 2007). What is less clear is whether this local autonomic dysfunction is a reflection of a more generalised autonomic neuropathy. Young et al. showed that subjects with painful DPN had a higher ratio of autonomic to electrophysiological abnormality compared to painless DPN (Young et al., 1986). In contrast, Veves et al. showed no difference in autonomic function between painful and painless DPN (Veves et al., 1994). 
One of the reasons why previous studies looking at generalised autonomic function in painful DPN may have shown mixed results is that they have generally used conventional tests of autonomic function (cardiovascular reflex tests), which only pick up abnormalities in the more advanced stages. Current recommendations for diagnosis of CAN are based on a consensus statement from the San Antonio Conference on Diabetic Neuropathy in 1988 and involve a battery of detailed cardiovascular reflex tests (ADA, 1988). They recommended three tests of heart rate control, which were heart rate response to (i) deep breathing, (ii) standing, and (iii) the Valsalva manoeuvre. Two tests of blood pressure control were also recommended: blood pressure response to (i) standing/passive tilting and (ii) sustained handgrip. The majority of these tests require specialist equipment and training, and are time consuming to perform. An additional drawback is that they require active subject participation and compliance.
Spectral analysis of HRV, in contrast, has several advantages over conventional techniques. In addition to being a more sensitive measure of autonomic dysfunction, it is (i) easy to perform with limited specialist training; (ii) does not require expensive and cumbersome equipment; (iii) is very quick to carry out; and (iv) is not affected by subject variability. It is based on assessing the variation of the R-R interval (time between consecutive heart beats) as a function of frequency in a resting ECG.
The R-R interval variation at rest represents fine-tuning of the beat-to-beat control mechanisms. Vagal afferent stimulation leads to reflex excitation of vagal efferent activity and inhibition of sympathetic efferent activity. The opposite reflex effects are mediated by the stimulation of sympathetic afferent activity. Efferent vagal activity is also under ‘tonic’ restraint by cardiac afferent sympathetic activity. Efferent sympathetic and vagal activities directed to the sinus node are characterised by discharges that are largely synchronous with each cardiac cycle. They can be modulated by central (e.g., vasomotor and respiratory centres) and peripheral (e.g., oscillation in arterial pressure and respiratory movements) oscillators. These oscillators generate rhythmic fluctuations in efferent neural discharge that manifest as short and long-term oscillation in the heart rate. Analysis of these intrinsic rhythms may permit inferences on the state and function of (i) central oscillators; (ii) sympathetic and vagal efferent activity; (iii) humoral factors; and (iv) the sinus node.
The efferent vagal activity is a major contributor to the HF component, as seen in clinical and experimental observations of autonomic manoeuvres such as electrical vagal stimulation, muscarinic receptor blockade, and vagotomy. More controversial is the interpretation of the LF component, which is considered by some as a marker of sympathetic modulation (Montano et al., 1994) and by others as a parameter that includes both sympathetic and vagal influences (Appel et al., 1989). Other indices (e.g., LF/HF ratio) assess the controlled and balanced activity of the two branches of the autonomic nervous system. 
Although the results of this study are consistent with the hypothesis of autonomic dysfunction being involved in the pathophysiology of painful DPN, the cross-sectional design means that whether it has a direct role or is simply a para-phenomenon is not yet clear. It seems unlikely that this association is a reflection of the severity of neuropathy, as there were no significant differences between painful and painless DPN in either the NCS or in the majority of individual parameters of nerve function. Perhaps, however, the most important message of this study for clinical practice is that the presence of painful symptoms should increase the physician’s vigilance for the presence of autonomic neuropathy, which still often goes undetected.
One possible confounder to these results is the greater use of drugs that may interfere with HRV in the DPN groups. Pharmacological agents such as b-blockers, ACE inhibitors and calcium channel blockers generally result in increases in HRV (Nolan et al., 2008). Therefore, if anything, their usage would lead to an underestimation of difference seen between the groups.
This study also demonstrated subjects with no evidence of DPN had lower HF, compared to HV. No differences were detected between these two groups using the conventional tests. HF is thought to be a marker of parasympathetic function and these findings suggest that it can be detected early, before any manifestation of symptoms and when conventional tests are still normal. It also suggests that parasympathetic autonomic dysfunction is the first abnormality to arise in the development of CAN. This is consistent with previous findings (Weston et al., 1998).   





5  A Model to Detect Autonomic Dysfunction using Heart Rate Variability Analysis
5.1  Introduction
As already discussed, CAN is a serious complication of diabetes and carries up to a five-fold increased risk of mortality (Vinik et al., 2003). This high mortality rate is related in large part to silent myocardial ischaemia, cardiac arrhythmias, and cardio-respiratory instability. Despite its relationship to an increased risk of cardiovascular mortality and its association with significant morbidity, the importance of CAN is not fully appreciated and it frequently goes undiagnosed. A major reason for this is that, whilst severe symptomatic CAN is relatively uncommon, many people have sub-clinical or asymptomatic CAN.
Unlike with other microvascular complications of diabetes, such as retinopathy and nephropathy, current clinical practice does not involve screening for CAN using a well defined biomarker. Arguably, it is even more important to identify CAN at an early stage, as it is associated with much higher morbidity and premature mortality, than many of the other complications currently screened for. Current recommendations for diagnosis of CAN are based on a consensus statement from the San Antonio Conference on Diabetic Neuropathy in 1988 and involve a battery of detailed cardiovascular reflex tests (ADA, 1988). They recommended three tests of heart rate control, which were heart rate response to (i) deep breathing, (ii) standing, and (iii) the Valsalva manoeuvre. Two tests of blood pressure control were also recommended: blood pressure response to (i) standing/passive tilting and (ii) sustained handgrip. The majority of these tests require specialist equipment and training, and are time consuming to perform. An additional confounder is that they require active subject participation and compliance. This has led to these tests being restricted to a minority of people, mainly those with advanced DAN who have already developed symptoms.
The reported prevalence of CAN varies, depending on the cohort studied and the methods of assessment. As an example, the prevalence of cardiac autonomic neuropathy, the most clinically important form of CAN, ranges from 8% in newly diagnosed subjects with Type 1 diabetes, to 90% in subjects selected for pancreas transplantation (Ziegler et al., 1992b, Kennedy et al., 1995). In the general diabetes population, a prevalence of between 16.6% and 34.3% has been reported (Neil et al., 1989, O'Brien et al., 1986). Others have suggested that due the complexity of the dysfunction, the numbers are even larger than these studies report.
There is now good evidence that CAN is associated with a variety of adverse, mainly cardiovascular, outcomes (Vinik et al., 2003, O'Brien et al., 1991). Many of the studies have, however, been observational and there is some debate that these associations may be in part related to the presence of other co-morbid conditions. There is a lack of long-term prospective studies looking both at the natural history of CAN and the risk factors involved in both its development and progression. Toyry et al. have shown in a small group of subjects that over 10 years, the presence of CAN at baseline was associated with an increased incidence of cardiovascular death compared to those without CAN (13% vs. 3%) and was independent of conventional cardiovascular risk factors (Toyry et al., 1996). One of the difficulties in obtaining this detailed prospective evidence stems from the complexity of the tests required to diagnose CAN. As a result, large-scale prospective studies will often only use one or two of the more easily performed tests and therefore potentially under-estimate the prevalence and incidence of CAN (Tesfaye et al., 2005).
A recent statement by the ADA (Boulton et al., 2005) recommended annual screening for CAN to be instituted at diagnosis in Type 2 diabetes and 5 years after the diagnosis of Type 1 diabetes. Screening should comprise of a history and clinical examination for symptoms or signs of autonomic dysfunction. If positive, appropriate diagnostic tests and treatments should be instituted. However, as both symptoms and clinical signs occur only in subjects with more advanced forms of CAN, a large number of patients with sub-clinical CAN will be missed. 
Earlier identification of these high-risk individuals would allow for the deployment of strategies to improve long-term outcomes. There is now growing evidence that earlier interventions, such as establishment of tight glycaemic control, early use of pharmacological agents such as ACE inhibitors and aspirin, as well as lifestyle modifications, can result in better long-term outcomes (Vinik et al., 2003, Boulton et al., 2005). If diagnosis is delayed until the development of symptoms, the outcome is extremely poor, with 5-year survival rates of only 50% (Toyry et al., 1996, Ewing et al., 1980). 
In this context, CAN may fulfil many of the Wilson-Jungner criteria for a screening programme (Wilson and Jungner, 1968). The first stage of determining whether screening for sub-clinical CAN is important is to better understand its natural history and to prospectively determine that early intervention alters this natural history. The current gold standard method for detecting sub-clinical CAN is baroreceptor sensitivity (BRS) testing. Standard cardiovascular tests and BRS testing are too complex tools to be administered either in large-scale prospective studies or in a potential screening programme. There is a need for the development of novel biomarkers that (i) are easy to perform with limited specialist training; (ii) do not require expensive and cumbersome equipment; and (iii) do not take a long time to carry out. Spectral analysis of HRV fulfils these requirements. As demonstrated in a number of previous studies (Freeman et al., 1991, Howorka et al., 1998), as well as the previous study in this thesis, it also seems to have a further advantage over the standard tests in that it measures a variety of different parameters that are a more sensitive measure of autonomic dysfunction. These measurements may act as novel biomarkers for different types and stages of autonomic neuropathy. There is, however, a lack of standardisation of key aspects of these techniques, such as the duration and circumstances of the ECG recording. This is despite recommendations from an international consensus panel recommending a 5 minute recording of a stationary system as the preferred method (Malik, 1996).  There has also been no comparison with the gold standard of BRS testing. As a result, there is currently no consensus on the definition of what represents an abnormal result and this has hindered its clinical application. In addition, if this test is to be useful in the clinical setting, it would be important to be able to discriminate between the groups. 
5.2  Hypothesis
1. Spectral analysis of HRV, based on a 5 minute ECG at rest, is a sensitive method of detecting subclinical CAN compared to the gold standard of BRS.
2. A model incorporating multiple parameters of HRV analysis will have reasonable sensitivity and specificity to detect both subclinical and established CAN to be of clinical utility.
5.3  Aims
The aim of this study was to validate short-term HRV analysis as a sensitive method of detecting early autonomic dysfunction when compared to the current gold standard of BRS. A second aim was to build a diagnostic model using the different parameters measured using discriminant function analysis and test its validity.
5.3  Subjects and Methods
5.3.1  Subjects
138 unselected subjects with T1DM (consecutive consenting patients attending a hospital outpatient clinic and fulfilling the inclusion criteria) underwent conventional AFT, BRS testing and HRV analysis.  All subjects were aged between 18-70 years. Subjects with non-diabetic neuropathies, history of alcohol excess, significant left ventricular dysfunction (≥ NYHA Class III) or other cardiac problems that precluded HRV analysis, were excluded. All subjects gave written, informed consent before participation in the study, which had prior approval by the South Sheffield Regional Ethics Committee.
Conventional AFT were used as the gold standard to detect CAN, whilst BRS was used as the gold standard to detect subclinical CAN in subjects with normal conventional AFT. The groups were classified as described in table 15.

No CAN	Normal AFT and BRS
Subclinical CAN	Normal AFT and abnormal BRS
CAN	Abnormal AFT and BRS
Table 15 Classification of CAN Type

5.3.2  Baroreceptor Sensitivity Testing
Changes in BP are sensed by pressure sensitive areas (baroreceptors) within the carotid sinus and aortic arch. The afferent fibres travel to the brainstem, where parasympathetic and sympathetic responses are generated. These regulate the changes in BP by effects on both the heart rate (cardiac output) and vasoconstriction or vasodilation of arterial vessels. BRS testing measures changes in heart rate in response to changes in BP. In the case of this study it measures the changes in response to the spontaneous variations in BP that occur physiologically at rest.
Longitudinal studies have demonstrated that BRS is an important independent predictor of mortality in people with diabetes (Gerritsen et al., 2001). Several studies have also shown that BRS abnormalities occur before abnormalities of conventional AFT (Frattola et al., 1997, Weston et al., 1998) and may be reversible at this stage (Rosengard-Barlund et al., 2009). Similar prognostic data is not yet available for other sensitive methods of assessing autonomic function (such as HRV analysis) and as a result BRS is widely regarded as the gold standard method for detecting CAN.
Although BRS is a sensitive method to detect autonomic dysfunction and relatively quick to carry out, it requires expensive equipment and a degree of specialist training and as a result is not in widespread clinical use.
BRS was measured using the Portapres device (Finapres Medical Systems, Amsterdam, The Netherlands) using dedicated software provided by the manufacturer.

5.3.3  Statistical Analysis
ANOVA with Bonferroni post-hoc testing was used to calculate significance of any differences between the groups.





RR	Mean of the intervals between successive normal R-waves -  so called normal to normal (NN) intervals
SDNN	Standard deviation of the NN intervals
RMSSD	Square root of the mean squared differences of successive NN intervals
Frequency Domain Parameters
TP	Total power of the spectrum (0.003-0.4 Hz)
VLF	Very low frequency component (0.003-0.04 Hz)
LF	Low frequency component (0.4-0.15 Hz)
HF	High frequency component (0.15-0.4 Hz)
LF/HF	LF to HF ratio (a measure of sympathetic and parasympathetic balance)
Table 16 HRV parameters used in discriminant function analysis model

Internal cross-validation was then used to test the validity of the model, using the leave-one-out method; each case is classified by the functions derived from all cases other than that case.
Two analyses were carried out to ascertain:
1.	the ability of the model to correctly classify which of the 3 groups individual subjects fell into and
2.	the ability of the model to detect any CAN (i.e. the subclinical CAN and CAN groups were combined).

5.3.4  Discriminant Function Analysis




5.4.1  Baseline Characteristics and Group Distribution
Figure 15 shows the distribution of the subjects across the different CAN groups based on the AFT and BRS results.

Figure 15 Distribution of CAN Groups

Table 17 shows the baseline characteristics of the 3 groups. Not surprisingly, subjects with CAN were older, had longer duration of diabetes, poorer glycaemic control and higher SBP compared to the other 2 groups. There were no significant differences between no CAN and subclinical CAN, except in the BRS results.

	No CAN	Subclinical CAN	CAN	P-value (ANOVA)
Number (%Female)	74 (40)	39 (51)	25 (48)	-
Age (yrs)	36.6±9.6	33.0±13.6	44.6±10.0	<0.001





Table 17 Baseline characteristics of the AFT groups
Data are means ± SD, unless otherwise indicated
5.4.2  Discriminant Function Model











Table 18 Individual HRV measurements in AFT groups
Data are means(±SD), unless otherwise indicated

Table 19 shows the results of the discriminant function analysis modelling when subjects were classified into 3 groups (no CAN, subclinical CAN and CAN). Within the original group (top half of table), the model correctly predicted 79% of the cases. When internal cross-validation was carried out (lower half of the table), the model still managed to correctly predict 72.5% cases. Of those with established CAN, only a tiny minority were misclassified as having no CAN (4.1% of the original group and 6.8% of the cross-validated group). This suggests the model performs very well and does not miss many people with CAN. In terms of its clinically utility, one could argue that misclassifying people with CAN as subclinical CAN or vice versa would have minimal impact on how these patient would be managed.
















Table 19 Three Group Analysis - No CAN vs. subclinical CAN vs. CAN
	79% of the original grouped cases were correctly classified








	%	No CAN	83.8	16.2	100.0	Positive predictive value	82%
		Any CAN	14.1	85.9	100.0	Negative predictive value	87%
Cross-validate	Count	No CAN	61	13	74	False positive rate	16%
		Any CAN	14	50	64	False negative rate	14%
	%	No CAN	82.4	17.6	100.0	Power	86%
		Any CAN	21.9	78.1	100.0
Table 20 Two Group Analysis – No CAN vs. any CAN
	84.8% of the original grouped cases were correctly classified.
	80.4% of the cross-validated grouped cases were correctly classified.


Figure 16 ROC Curve for no CAN vs. any CAN
AUC = 0.919 (p < 0.0001)
5.4.3  Correlation with BRS
There was also a strong correlation in the group as a whole between the discriminant score derived from the model and the BRS value (r=0.78), as illustrated in figure 17. The BRS value was log-transformed to adjust for skewness.


Figure 17 Correlation between discriminant score and BRS

5.5  Discussion
This study confirms that significant differences can be detected short-term HRV parameters in subjects with subclinical levels of CAN, as well as established CAN. These results are consistent with previous studies which have described reduced HRV in subjects with diabetes and normal conventional AFT (Ziegler et al., 1992a, Spallone et al., 1996). None of these studies however looked specifically at short-term HRV analysis.
In order for a test to be of diagnostic value, however, it is also important that we are able to dichotomise subjects into different groups. Using just a single measure (e.g. TP), although there are significant differences between the groups, there remains significant overlap between individual measurements in different groups, as shown in Figure 18. At a cut off of 2.62 (marked on the graph), although there is reasonable sensitivity to detect any CAN at 85%, this is at the expense of specificity at 41%. The area under the ROC curve was 0.84.

Figure 18 Individual TP measurements for no CAN and any CAN
Discriminant function analysis allows us to determine the optimal combination of a set of variables to build a diagnostic model that discriminates between the groups. This study shows that this model, which incorporates some basic demographic data and multiple variables derived from HRV analysis, has a high sensitivity and specificity to detect CAN and correlates strongly with the gold standard test of BRS. 
Not surprisingly the modelling performs better when trying to discriminate between 2 rather than 3 groups, when there is greater overlap between groups. It compares favourably with other simple screening tools used in screening for complications of diabetes. For example, the 10g monofilament test, used to screen for the presence of peripheral neuropathy has been reported to have a specificity of 96% (>5/8 attempts insensate) and a sensitivity of 77% (< 1/8 attempts insensate), with an area under the ROC of 0.72 (Perkins et al., 2001). Other studies have reported specificities of between 75% to 100% and sensitivities between 57% to 93% (Feng et al., 2009). 
HRV analysis is a simple and quick test to perform (based on a 5 minute ECG recording) and could therefore easily be incorporated into a screening programme for CAN. It would also allow us to better study the natural history of autonomic neuropathy in large scale prospective trials. This study shows that it has the ability to detect CAN at a very early stage, before the onset of clinical symptoms, by when the outcome is extremely poor, with 5-year survival rates of only 50% (O'Brien et al., 1991). Early detection of this disorder might lead to a better prognosis for people with diabetes, by the deployment of interventions which will slow or possibly even reverse its progression. 
A major limitation of this study is that validation of the model was carried out internally. This almost inevitably flatters the performance of the model. In order to determine whether this model would truly help to discriminate between different levels of CAN, a further study applying the 2 models to an independent population dataset is required.
Further refinement of the model may improve the classification further. Further studies, on an independent population dataset, are now required to validate the model.


6  Final Discussion and Future Work
The primary aim of this body of research was to try and better understand the processes which underlie the development of DPN, and in particular what leads to some people developing chronic painful symptoms, whilst others develop painless DPN.  
The results of the thalamic MRS studies imply change in neuronal physiology or function, rather than neuronal loss in painless but not painful neuropathy. In contrast, the results within the somatosensory cortex, are suggestive of neuronal loss in subjects with painless neuropathy and this may be reflecting local cerebral parenchymal atrophy. Astrocyte dysfunction within a hyperglutaminergic state may be a key factor in the pathophysiology of chronic neuropathic pain. 
Using other techniques such as regional volumetry to assess regional grey and white matter atrophy may allow the determination of whether the differences observed are due to a general vascular effect of diabetes, an ascending “disuse atrophy” or a specific central effect of diabetic neuropathy. Other neuro-imaging techniques such as functional MRI, may help identify what other areas of the “pain matrix” are involved. Further studies are also required to study and track in more detail the neuronal connectivity between deep brain nuclei, the somatosensory cortex and affective brain regions that make up the pain matrix in subjects with painful and painless diabetic neuropathy, using novel techniques such as event related fMRI and diffusion tractography.
The autonomic function studies showed that painful DPN was associated with greater autonomic dysfunction than painless DPN and it may be that localised autonomic dysfunction at the level of the peripheral nerve has a role to play in pain generation. 
The cross-sectional nature of both the MRS and autonomic function studies mean that it is difficult to assign causation to the changes that have been observed. There is a need for longitudinal studies to better understand the relationships between these changes and the different types of diabetic neuropathy.
Painful diabetic neuropathy is not a single entity. For reasons that are still unclear, it presents with heterogeneous symptoms. It may be that there are differing patterns of disruption of both the peripheral and central “pain matrix” within these different syndromes. Further more detailed studies looking at different types of painful neuropathy (e.g. those with and without tactile allodynia) may help elucidate this enigma.
As well as clarifying disease mechanisms, identifying the neural correlates of pain-processing in diabetic neuropathy will result in opportunities to target specific components of the pain pathway pharmacologically. Combination of functional MRI (fMRI) and drug administration, often termed pharmacological fMRI, may prove useful in the future development and assessment of new analgesic compounds.
Finally, an important by-product of this research has been the development of a simple tool (short term HRV analysis), to detect autonomic dysfunction. It is potentially an early biomarker of CAN in diabetes that could prove useful for screening, diagnosis, and monitoring disease progression whilst being sufficiently simple to be used in routine clinical care. The first step in assessing HRV analysis as a potential biomarker is to determine its ability to distinguish between those with and without CAN (concurrent validity) in a cross-sectional analysis of subjects with a broad spectrum of CAN. The final study has gone a long way towards establishing this. The next step is to validate the model further by assessment with an independent dataset. The second important utility of a biomarker, known as predictive validity, is the ability to identify, in those without CAN at baseline, which individuals are likely to subsequently develop clinically relevant disease during prospective follow-up.  If such a biomarker is developed, those with subclinical or incipient disease could be identified and targeted for preventive therapy. This clearly requires a longitudinal prospective study. There may also be the opportunity to refine the model further. A potentially interesting technique is the use of a more sophisticated model using artificial neural networks (ANN). ANN is a mathematical model based on the properties of natural neurons, which learns and recognises patterns in ways that are similar to humans. The network is trained with elements from a data set and applies that knowledge to identify specific events (prediction) or classify the elements of different data sets (classification) (Ramesh et al., 2004). In this case, the network would be fed (input stimuli) with characteristics extracted from the HRV analysis and, after training, would classify new input data sets (HRV parameters for new subjects) into the different groups.
In summary, these studies have demonstrated that changes in neuronal physiology and function within both the central and autonomic nervous system may be important in the pathogenesis of painful DPN. They have demonstrated that DPN is a disease that affects the entire nervous system and should trigger a critical rethinking of the disorder.
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